Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 6 years
- Director since
- 2023
6 years of board service in total across 3 boards, counting each seat separately. Longest: Genelux Corporation, 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
NewAmsterdam Pharma Company N.V. June 2, 202698.9%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 4, 2026 | NewAmsterdam Pharma Company N.V. | Open-market sale | −1,600 | $25.32 | $40,512 |
| Aug 3, 2026 | MBX Biosciences Inc. | Grant or award | +28,000 | — | — |
| Jul 1, 2026 | Genelux Corporation | Open-market sale | −12,000 | $2.91 | $34,920 |
| Jun 16, 2026 | Genelux Corporation | Grant or award | +28,409 | — | — |
| Jan 7, 2026 | NewAmsterdam Pharma Company N.V. | Grant or award | +3,400 | — | — |
| Aug 27, 2025 | Genelux Corporation | Grant or award | +22,283 | — | — |
| Jan 7, 2025 | NewAmsterdam Pharma Company N.V. | Grant or award | +6,960 | — | — |
| Aug 1, 2024 | Genelux Corporation | Grant or award | +39,541 | — | — |
| May 29, 2024 | Genelux Corporation | Open-market purchase | +6,250 | — | — |
| Feb 13, 2024 | Arcutis Biotherapeutics Inc. | Grant or award | +2,793 | — | — |
| Feb 13, 2024 | Arcutis Biotherapeutics Inc. | Grant or award | +8,572 | — | — |
| Sep 13, 2023 | Genelux Corporation | Open-market sale | −900 | $20.78 | $18,702 |
| Sep 11, 2023 | Genelux Corporation | Grant or award | +6,920 | — | — |
Questions about John W. Smither
What boards is John W. Smither on?
John W. Smither sits on the boards of Attovia Therapeutics Inc., Genelux Corporation and NewAmsterdam Pharma Company N.V.
How long has John W. Smither served on boards?
Our records show at least 6 years of board service across 3 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.